Cargando…
Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune resp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522836/ https://www.ncbi.nlm.nih.gov/pubmed/37771588 http://dx.doi.org/10.3389/fimmu.2023.1230264 |
_version_ | 1785110436492869632 |
---|---|
author | Tsai, Yi-Giien Liao, Pei-Fen Hsiao, Kai-Hung Wu, Hung-Ming Lin, Ching-Yuang Yang, Kuender D. |
author_facet | Tsai, Yi-Giien Liao, Pei-Fen Hsiao, Kai-Hung Wu, Hung-Ming Lin, Ching-Yuang Yang, Kuender D. |
author_sort | Tsai, Yi-Giien |
collection | PubMed |
description | Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE. |
format | Online Article Text |
id | pubmed-10522836 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105228362023-09-28 Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus Tsai, Yi-Giien Liao, Pei-Fen Hsiao, Kai-Hung Wu, Hung-Ming Lin, Ching-Yuang Yang, Kuender D. Front Immunol Immunology Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune responses in SLE. Additionally, CD8+ regulatory T cells, type 1 regulatory T cells (Tr1), and B regulatory cells also have a less well-defined role in the pathogenesis of SLE. Elucidation of the roles of various Treg subsets dedicated to immune homeostasis will provide a novel therapeutic approach that governs immune tolerance for the remission of active lupus. Diminished interleukin (IL)-2 production is associated with a depleted Treg cell population, and its reversibility by IL-2 therapy provides important reasons for the treatment of lupus. This review focuses on the pathogenesis and new therapeutics of human Treg subsets and low-dose IL-2 therapy in clinical benefits with SLE. Frontiers Media S.A. 2023-09-12 /pmc/articles/PMC10522836/ /pubmed/37771588 http://dx.doi.org/10.3389/fimmu.2023.1230264 Text en Copyright © 2023 Tsai, Liao, Hsiao, Wu, Lin and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Tsai, Yi-Giien Liao, Pei-Fen Hsiao, Kai-Hung Wu, Hung-Ming Lin, Ching-Yuang Yang, Kuender D. Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus |
title | Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus |
title_full | Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus |
title_fullStr | Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus |
title_full_unstemmed | Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus |
title_short | Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus |
title_sort | pathogenesis and novel therapeutics of regulatory t cell subsets and interleukin-2 therapy in systemic lupus erythematosus |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10522836/ https://www.ncbi.nlm.nih.gov/pubmed/37771588 http://dx.doi.org/10.3389/fimmu.2023.1230264 |
work_keys_str_mv | AT tsaiyigiien pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus AT liaopeifen pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus AT hsiaokaihung pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus AT wuhungming pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus AT linchingyuang pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus AT yangkuenderd pathogenesisandnoveltherapeuticsofregulatorytcellsubsetsandinterleukin2therapyinsystemiclupuserythematosus |